Abstract
Inosine 5-monophosphate dehydrogenase (IMPDH) catalyzes the first committed step of guanosine 5-monophosphate (GMP) biosynthesis, and thus regulates the guanine nucleotide pool, which in turn governs proliferation. Human IMPDHs are validated targets for immunosuppressive, antiviral and anticancer drugs, but as yet microbial IMPDHs have not been exploited in antimicrobial chemotherapy. Selective inhibitors of IMPDH from Cryptosporidium parvum have recently been discovered that display anti-parasitic activity in cell culture models of infection. X-ray crystal structure and mutagenesis experiments identified the structural features that determine inhibitor susceptibility. These features are found in IMPDHs from a wide variety of pathogenic bacteria, including select agents and multiply drug resistant strains. A second generation inhibitor displays antibacterial activity against Helicobacter pylori, demonstrating the antibiotic potential of IMPDH inhibitors.
Keywords: Antibacterial, Cryptosporidium parvum, guanine nucleotide, biosynthesis, Helicobacter pylori, IMPDH, inosine 5'- monophosphate dehydrogenase, select agents, Mycobacterium tuberculosis
Current Medicinal Chemistry
Title: The Antibiotic Potential of Prokaryotic IMP Dehydrogenase Inhibitors
Volume: 18 Issue: 13
Author(s): L. Hedstrom, G. Liechti, J. B. Goldberg and D. R. Gollapalli
Affiliation:
Keywords: Antibacterial, Cryptosporidium parvum, guanine nucleotide, biosynthesis, Helicobacter pylori, IMPDH, inosine 5'- monophosphate dehydrogenase, select agents, Mycobacterium tuberculosis
Abstract: Inosine 5-monophosphate dehydrogenase (IMPDH) catalyzes the first committed step of guanosine 5-monophosphate (GMP) biosynthesis, and thus regulates the guanine nucleotide pool, which in turn governs proliferation. Human IMPDHs are validated targets for immunosuppressive, antiviral and anticancer drugs, but as yet microbial IMPDHs have not been exploited in antimicrobial chemotherapy. Selective inhibitors of IMPDH from Cryptosporidium parvum have recently been discovered that display anti-parasitic activity in cell culture models of infection. X-ray crystal structure and mutagenesis experiments identified the structural features that determine inhibitor susceptibility. These features are found in IMPDHs from a wide variety of pathogenic bacteria, including select agents and multiply drug resistant strains. A second generation inhibitor displays antibacterial activity against Helicobacter pylori, demonstrating the antibiotic potential of IMPDH inhibitors.
Export Options
About this article
Cite this article as:
Hedstrom L., Liechti G., B. Goldberg J. and R. Gollapalli D., The Antibiotic Potential of Prokaryotic IMP Dehydrogenase Inhibitors, Current Medicinal Chemistry 2011; 18 (13) . https://dx.doi.org/10.2174/092986711795590129
DOI https://dx.doi.org/10.2174/092986711795590129 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
GqPCR-mediated Signalling in the Spotlight: From Visualization Towards Dissection and Quantification
Current Pharmaceutical Biotechnology The Possibilities and Pitfalls for Anti-Complement Therapies in Inflammatory Diseases
Current Drug Targets - Inflammation & Allergy Microwave Assisted Functionalization of Materials: from the Mesoscale to the Nanoscale
Current Organic Chemistry Nanosized Drug Delivery Systems for Direct Nose to Brain Targeting: A Review
Recent Patents on Drug Delivery & Formulation Genetically Modified Viruses Vaccines by Design
Current Pharmaceutical Biotechnology Turning Up the Pressure on Vascular Disease
Current Neurovascular Research 5HT1F- and 5HT7-Receptor Agonists for the Treatment of Migraines
CNS & Neurological Disorders - Drug Targets Carbonic Anhydrase Inhibitors
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Targeted Blockade of TARP-γ8-Associated AMPA Receptors: Anticonvulsant Activity with the Selective Antagonist LY3130481 (CERC-611)
CNS & Neurological Disorders - Drug Targets Non-viral Gene Delivery and Therapeutics Targeting to Brain
Current Nanoscience Neurosarcoidosis
Current Neuropharmacology The Clinical and Immunological Features of Patients with Primary Antibody Deficiencies
Endocrine, Metabolic & Immune Disorders - Drug Targets Delirium in Older Patients – A Review
Current Psychiatry Reviews New Drugs and Treatment Regimens
Current Respiratory Medicine Reviews Therapeutic Targets for the Prevention of Type 1 Diabetes Mellitus
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Transendothelial Migration of Monocytes: The Underlying Molecular Mechanisms and Consequences of HIV-1 Infection
Current HIV Research Brucellosis Serostatus Among Pregnant Women with Spontaneous Abortion and Stillbirth
Current Women`s Health Reviews The Therapeutic Potential of Melatonin in Neurological Disorders
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Antimicrobial Peptide rBPI21: A Translational Overview from Bench to Clinical Studies
Current Protein & Peptide Science The Blood-Brain Barrier in Multiple Sclerosis: microRNAs as Key Regulators
CNS & Neurological Disorders - Drug Targets